Research groups
Patrick Julier
OCTRU Head of Programming
I have over 25 years’ experience in the IT industry, working in manufacturing, finance, telecommunications and the public sector before working in Clinical Trials when I joined the Oncology Clinical Trials Office (OCTO) in 2004.
I am OCTRU's Head of Programming and lead a team of 5 programmers/database officers. I joined OCTRU in October 2013 when we had no IT systems to speak of. Since then we have developed 5 systems and installed and support 4 off-the-shelf systems.
We look forward to taking these systems forward and to continue providing a responsive and professional service to all the Clinical Trials Units within the OCTRU family.
Recent publications
The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT
Journal article
Cook JA. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 25
Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
Journal article
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 42
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
Journal article
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 43 - 44
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Journal article
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 45 - 46
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Journal article
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 47 - 48